A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion

Mitchell D Creinin, Josep L L Carbonell, Jill L. Schwartz, L. Varela, R. Tanda

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

A prospective multicenter, randomized trial was performed to evaluate if moistened misoprostol results in a more rapid abortion and a higher rate of complete abortion compared with dry misoprostol when administered intravaginally for medical abortion after methotrexate. A total of 240 pregnant women ≤49 days gestation seeking elective abortion received 50 mg/m2 methotrexate intramuscularly followed 5-6 days later by 800 μg misoprostol vaginally. The misoprostol dose was repeated in 1-2 days if the abortion did not occur. Group 1 moistened the misoprostol before administration and group 2 used dry tablets. There was no statistically significant difference in the cumulative rate of abortion after the first misoprostol dose (73.0% vs 71.3%, p = 0.87), second misoprostol dose (84.1% vs 81.1%, p = 0.65), or by 35 days after methotrexate administration (95.2% vs 91.8%, p = 0.40) between groups 1 and 2, respectively. The proportion of subjects with embryonic cardiac activity 2 weeks after methotrexate injection was greater in group 2 (5.7%, 95% confidence interval [CI] 1.0%, 9.9%) than in group 1 (2.4%, 95% CI 0%, 5.0%), although not statistically significant (p = 0.21). The immediate success rate in Pittsburgh was greater, albeit not statistically, for the women that moistened the misoprostol (87% vs 76%, p = 0.19); these rates were also not statistically different in Havana (82% vs 86%, p = 0.62). The rate of side effects after methotrexate was not different between groups but women in group 1 had significantly more diarrhea (36% vs 21%, p = 0.02) and fever/warmth/chills (44% vs 30%, p = 0.04). Moistening misoprostol before vaginal administration in a medical abortion regimen with methotrexate does not statistically improve efficacy. This trial demonstrates the importance of prospective, randomized studies to prove the relative efficacy of any medical abortion treatment regimen.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalContraception
Volume59
Issue number1
DOIs
StatePublished - Jan 1999
Externally publishedYes

Fingerprint

Intravaginal Administration
Misoprostol
Methotrexate
Induced Abortion
Confidence Intervals
Chills
Tablets
Multicenter Studies
Pregnant Women
Diarrhea
Fever
Prospective Studies

Keywords

  • Medical abortion treatment regimen
  • Methotrexate
  • Misoprostol
  • Side effects

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. / Creinin, Mitchell D; Carbonell, Josep L L; Schwartz, Jill L.; Varela, L.; Tanda, R.

In: Contraception, Vol. 59, No. 1, 01.1999, p. 11-16.

Research output: Contribution to journalArticle

Creinin, Mitchell D ; Carbonell, Josep L L ; Schwartz, Jill L. ; Varela, L. ; Tanda, R. / A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. In: Contraception. 1999 ; Vol. 59, No. 1. pp. 11-16.
@article{b04854eaa8e440cdbb9ae4309dc0d150,
title = "A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion",
abstract = "A prospective multicenter, randomized trial was performed to evaluate if moistened misoprostol results in a more rapid abortion and a higher rate of complete abortion compared with dry misoprostol when administered intravaginally for medical abortion after methotrexate. A total of 240 pregnant women ≤49 days gestation seeking elective abortion received 50 mg/m2 methotrexate intramuscularly followed 5-6 days later by 800 μg misoprostol vaginally. The misoprostol dose was repeated in 1-2 days if the abortion did not occur. Group 1 moistened the misoprostol before administration and group 2 used dry tablets. There was no statistically significant difference in the cumulative rate of abortion after the first misoprostol dose (73.0{\%} vs 71.3{\%}, p = 0.87), second misoprostol dose (84.1{\%} vs 81.1{\%}, p = 0.65), or by 35 days after methotrexate administration (95.2{\%} vs 91.8{\%}, p = 0.40) between groups 1 and 2, respectively. The proportion of subjects with embryonic cardiac activity 2 weeks after methotrexate injection was greater in group 2 (5.7{\%}, 95{\%} confidence interval [CI] 1.0{\%}, 9.9{\%}) than in group 1 (2.4{\%}, 95{\%} CI 0{\%}, 5.0{\%}), although not statistically significant (p = 0.21). The immediate success rate in Pittsburgh was greater, albeit not statistically, for the women that moistened the misoprostol (87{\%} vs 76{\%}, p = 0.19); these rates were also not statistically different in Havana (82{\%} vs 86{\%}, p = 0.62). The rate of side effects after methotrexate was not different between groups but women in group 1 had significantly more diarrhea (36{\%} vs 21{\%}, p = 0.02) and fever/warmth/chills (44{\%} vs 30{\%}, p = 0.04). Moistening misoprostol before vaginal administration in a medical abortion regimen with methotrexate does not statistically improve efficacy. This trial demonstrates the importance of prospective, randomized studies to prove the relative efficacy of any medical abortion treatment regimen.",
keywords = "Medical abortion treatment regimen, Methotrexate, Misoprostol, Side effects",
author = "Creinin, {Mitchell D} and Carbonell, {Josep L L} and Schwartz, {Jill L.} and L. Varela and R. Tanda",
year = "1999",
month = "1",
doi = "10.1016/S0010-7824(98)00142-5",
language = "English (US)",
volume = "59",
pages = "11--16",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion

AU - Creinin, Mitchell D

AU - Carbonell, Josep L L

AU - Schwartz, Jill L.

AU - Varela, L.

AU - Tanda, R.

PY - 1999/1

Y1 - 1999/1

N2 - A prospective multicenter, randomized trial was performed to evaluate if moistened misoprostol results in a more rapid abortion and a higher rate of complete abortion compared with dry misoprostol when administered intravaginally for medical abortion after methotrexate. A total of 240 pregnant women ≤49 days gestation seeking elective abortion received 50 mg/m2 methotrexate intramuscularly followed 5-6 days later by 800 μg misoprostol vaginally. The misoprostol dose was repeated in 1-2 days if the abortion did not occur. Group 1 moistened the misoprostol before administration and group 2 used dry tablets. There was no statistically significant difference in the cumulative rate of abortion after the first misoprostol dose (73.0% vs 71.3%, p = 0.87), second misoprostol dose (84.1% vs 81.1%, p = 0.65), or by 35 days after methotrexate administration (95.2% vs 91.8%, p = 0.40) between groups 1 and 2, respectively. The proportion of subjects with embryonic cardiac activity 2 weeks after methotrexate injection was greater in group 2 (5.7%, 95% confidence interval [CI] 1.0%, 9.9%) than in group 1 (2.4%, 95% CI 0%, 5.0%), although not statistically significant (p = 0.21). The immediate success rate in Pittsburgh was greater, albeit not statistically, for the women that moistened the misoprostol (87% vs 76%, p = 0.19); these rates were also not statistically different in Havana (82% vs 86%, p = 0.62). The rate of side effects after methotrexate was not different between groups but women in group 1 had significantly more diarrhea (36% vs 21%, p = 0.02) and fever/warmth/chills (44% vs 30%, p = 0.04). Moistening misoprostol before vaginal administration in a medical abortion regimen with methotrexate does not statistically improve efficacy. This trial demonstrates the importance of prospective, randomized studies to prove the relative efficacy of any medical abortion treatment regimen.

AB - A prospective multicenter, randomized trial was performed to evaluate if moistened misoprostol results in a more rapid abortion and a higher rate of complete abortion compared with dry misoprostol when administered intravaginally for medical abortion after methotrexate. A total of 240 pregnant women ≤49 days gestation seeking elective abortion received 50 mg/m2 methotrexate intramuscularly followed 5-6 days later by 800 μg misoprostol vaginally. The misoprostol dose was repeated in 1-2 days if the abortion did not occur. Group 1 moistened the misoprostol before administration and group 2 used dry tablets. There was no statistically significant difference in the cumulative rate of abortion after the first misoprostol dose (73.0% vs 71.3%, p = 0.87), second misoprostol dose (84.1% vs 81.1%, p = 0.65), or by 35 days after methotrexate administration (95.2% vs 91.8%, p = 0.40) between groups 1 and 2, respectively. The proportion of subjects with embryonic cardiac activity 2 weeks after methotrexate injection was greater in group 2 (5.7%, 95% confidence interval [CI] 1.0%, 9.9%) than in group 1 (2.4%, 95% CI 0%, 5.0%), although not statistically significant (p = 0.21). The immediate success rate in Pittsburgh was greater, albeit not statistically, for the women that moistened the misoprostol (87% vs 76%, p = 0.19); these rates were also not statistically different in Havana (82% vs 86%, p = 0.62). The rate of side effects after methotrexate was not different between groups but women in group 1 had significantly more diarrhea (36% vs 21%, p = 0.02) and fever/warmth/chills (44% vs 30%, p = 0.04). Moistening misoprostol before vaginal administration in a medical abortion regimen with methotrexate does not statistically improve efficacy. This trial demonstrates the importance of prospective, randomized studies to prove the relative efficacy of any medical abortion treatment regimen.

KW - Medical abortion treatment regimen

KW - Methotrexate

KW - Misoprostol

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=0033009024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033009024&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(98)00142-5

DO - 10.1016/S0010-7824(98)00142-5

M3 - Article

C2 - 10342081

AN - SCOPUS:0033009024

VL - 59

SP - 11

EP - 16

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 1

ER -